Physician profile
Mary Brown
NPI 1558866806
$1,099.44
in general payments reported to CMS, 2019-2025
19 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $243 · 2023: $243 · 2024: $300 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692 · Education: $31.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.70 |
| Education | $31.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $159.11 | 2022-2025 | |
| Pfizer INC. | $82.57 | 2023-2024 | |
| Exact Sciences Corporation | $59.07 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $57.30 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $51.90 | 2022 | |
| Jazz Pharmaceuticals INC. | $44.77 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $38.05 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.43 | 2023-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $34.44 | 2024 | Airsupra |
| Lilly USA, LLC | $32.87 | 2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $32.24 | 2025 | Iclusig |
| Opko Pharmaceuticals, LLC | $31.71 | 2024 | Rayaldee |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.30 | 2025 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.41 | 2025 | Trelegy Ellipta |
| Apria Healthcare LLC | $17.58 | 2021 | |
| Abbott Laboratories | $14.32 | 2024 | Freestyle Libre 3 |
| Corium, LLC | $12.79 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.